The picornavirus family includes rh...

The picornavirus family includes rhinoviruses and enteroviruses, which cause approximately individual half of common colds each year. Pleconaril is a recently made known oral drug that has been shown to inhibit viral replication in about 90 percent of rhinovirus serotype and more than 99 percent of enteroviruses. Hayden and colleagues investigated the efficacy and safety of pleconaril for treatment of the customary cold by examining the follows of two identical randomized, controll multicenter trials.

A total of 2096 patients were recruited, based onward self-reported cold symptoms of fewer than 24 hours' duration. Symptoms meriting inclusion were the port of rhinorrhea and at least single in kind other cold symptom (nasal congestion, sore throat, cough) Patients with febrile disease chronic cough, recent treatment for allergic rhinitis or asthma, immunodeficiency, or major medical comorbidity, and women who were pregnant or nursing were exclud Smoker were permitted in the trial.

Participants were randomized to receive pleconaril in a dosage of 400 mg three times daily for five days (1046 patients) or a matching placebo (1050 patients). solitary acetaminophen or dextromethorphan were allowed during the subject of attention for symptom relief, to impede possible masking of nasopharyngeal symptoms of polars Follow-up was conducted by telephone each other day until cold resolution, or 18 days post-infection. The least bit out rates among subjects in the placebo and physic treatment groups were 6.6 percent and 76 percent respectively. Participants recorded the severity of six bleak symptoms (rhinorrhea, nasal congestion, cough malaise, sore throat, and myalgias) twice daily. Nasal mucus samples were evaluated at baseline and in succession study days 3 and 6 for picornavirus infection on polymerase chain reaction assay for viral DNA. Overall, picornavirus infection was documented from polymerase chain reaction in 65 percent of self-reported cutting victims, and the rate did not differ significantly between placebo and pleconaril groups

In the couple studies, treatment with pleconaril was associated with a shorter duration of icy symptoms in patients with documented picornavirus infection. The mean reduction in duration of icy symptoms was one day (63 days with treatment, 73 days with placebo). The severity of gelid symptoms also was reduced in patients receiving pleconaril. Pleconaril was generally well tolerated, with sole slight increases above placebo rates for headache, diarrhea, and nausea.

The authors finish that the use of pleconaril within 24 hours of attack of the common cold was associated with a reduction in the duration and severity of biting symptoms.

Hayden FG et al. Efficacy and safety of oral pleconaril for treatment of raws due to picornaviruses in adults: deductions of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis June 15 2003;36:1523-32

EDITOR'S NOTE: From arm's extent the figures confirm what may be obscur at the "significant" p values institute scattered in the dense tables describing these large studies (i.e., not earnestly difference between pleconaril and placebo). single in kind would suspect that the reason for combining sum of two units identical trials was the borderline statistical significance of the first trial, and the questionable clinical significance (and cost) of converting a seven-day frosty into a six-day process, while taking medication three times daily.

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group